Samuel C. Blackman, MD, PhD
Chair, Industry Advisory Council
Senior Vice President, Head of Clinical Development
Silverback Therapeutics, Inc.
Samuel Blackman is Senior Vice President and Head of Clinical Development at Silverback Therapeutics in Seattle, Washington. For the past 9 years he has been focused on the early clinical development of novel cancer therapeutics and has held various positions of increasing responsibility within the pharmaceutical industry. Most recently, he served as Senior Medical Director at Juno Therapeutics where he was responsible for clinical development of novel immunotherapies for leukemia, including chimeric antigen receptor (CAR) T cell therapies and high-affinity T cell receptor (TCR) therapies. Previously, Samuel served as Executive Director and Head of Translational Medicine at Seattle Genetics where he was responsible for pre-clinical and early clinical development of novel antibody drug conjugate (ADC) therapeutics for cancer and lead a group of 30 physicians and scientists.